| Ytd | 10.60% | |
| 1y | -16.23% |
| Open | 4.71 | Prev Close | 4.78 | Low | 4.67 | High | 4.97 | Mkt Cap | 26.77M |
| Vol | 67.89K | Avg Vol | 537.81K | EPS | -4.23 | P/E | -1.13 | Forward P/E | -0.65 |
| Beta | -0.91 | Short Ratio | 0.69 | Inst. Own | 1.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.76 | 200-d Avg | 5.07 | 1yr Est | 48.33 |
CING News
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutio
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceuti
Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Pa
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on C
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutic
Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital P
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPT
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderat
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "M
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capit
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointe
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire
Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital P
Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE
On Wednesday, 348 companies hit new 52-week lows.
On Thursday, 89 companies hit new 52-week lows.
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The compan